Company Insights

ACB supplier relationships

Explore interactive graphBrowse insights index
ACB supplier relationship map

Aurora Cannabis (ACB) — Supplier profile and counterparty map

Aurora Cannabis operates as a global producer and distributor of medical cannabis products, monetizing through product sales across licensed markets and by accessing capital markets to fund operations and expansion. Revenue comes from finished product sales and wholesale distribution; equity capital programs such as at-the-market (ATM) offerings provide an additional liquidity lever that dilutes shareholders but preserves operating runway. For investors and operators assessing Aurora as a counterparty or supplier, the combination of operating losses, modest gross margins, and active use of equity distribution programs defines the commercial posture.

For a concise supplier-risk dashboard and real-time counterparty tracking, visit NullExposure’s homepage: https://nullexposure.com/

How Aurora runs the commercial engine

Aurora’s core operating model is product-centric: production facilities feed a wholesale and retail distribution network serving medical and recreational channels where legal. The business is capital-intensive and reliant on tight working-capital management and periodic equity injections to fund inventory, cultivation, and regulatory compliance. Financial metrics through the trailing twelve months show positive gross profit but negative net income and negative returns on equity and assets, signaling that operating cash flow and financing strategies are central to counterparty risk.

  • Contracting posture: Active engagement with capital-market intermediaries indicates a posture of on-demand financing rather than long-term, non-dilutive funding.
  • Concentration: Public-market trading and a limited set of capital agents are meaningful for liquidity management.
  • Criticality: For suppliers and partners, Aurora’s reliance on external financing and public-market access increases the importance of timely payments and contractual certainty.
  • Maturity: The company operates under mature public-company disclosure regimes but continues to restructure its capital and operations.

Explore supplier intelligence and counterparty analytics at https://nullexposure.com/

What the relationship data shows — the ATM program and market distribution

Aurora disclosed an at-the-market (ATM) offering arrangement in early FY2026 that directly ties its financing capacity to two counterparties captured in public notices: TD Securities (USA) LLC as the placement agent and NASDAQ as a venue option for sales. These relationships affect how Aurora converts equity into cash and therefore influence supplier credit and strategic risk.

TD Securities (USA) LLC

Aurora entered into a sales agreement dated February 4, 2026, with TD Securities (USA) LLC to issue and sell up to US$100,000,000 of common shares under an ATM program, giving Aurora the ability to raise equity incrementally through market sales. According to Aurora’s prospectus supplement and related SEC filings in March 2026, TD Securities acts as the agent to facilitate the distributions under the program. (Source: PR Newswire prospectus supplement and Aurora 6-K filings, March 2026.)

NASDAQ

Aurora specified that common share distributions under the ATM program will be executed as “at-the-market distributions” through the NASDAQ Capital Market or another U.S. marketplace at prevailing market prices, which defines the trade venue for incremental share issuance. The disclosure in the March 2026 prospectus supplement identifies NASDAQ as an explicit execution venue for those distributions. (Source: PR Newswire prospectus supplement, March 2026.)

Relationship implications for investors and operational partners

These counterparty ties create several concrete implications for suppliers and investors evaluating Aurora:

  • Liquidity access via ATM reduces immediate refinancing risk because Aurora can convert market liquidity to cash without negotiating a single large financing; however, this increases dilution risk for existing shareholders and can pressure equity value during active distributions.
  • Dependence on a sales agent and exchange-listed executions centralizes execution risk. If market conditions or the agent’s capacity shift, Aurora’s ability to raise the target US$100 million through the ATM program will be constrained, which in turn can pressure supplier credit terms.
  • Transparency and select governance controls are better under public ATM programs than under private placements, because prospectus supplements and 6-K filings create near-immediate public disclosure of the terms and usage.

Relationship-by-relationship summaries (plain English)

  • TD Securities (USA) LLC — Aurora appointed TD Securities (USA) LLC as agent under a sales agreement dated February 4, 2026, to sell up to US$100 million of common shares under an ATM program that allows incremental equity raises. According to Aurora’s prospectus supplement and 6-Ks filed in March 2026, TD Securities will execute the ATM distributions. (Source: PR Newswire prospectus supplement and Aurora 6-K filings, March 2026.)

  • NASDAQ — Aurora specified that ATM sales will be executed through the NASDAQ Capital Market or another U.S. marketplace at prevailing market prices, defining the exchange venue for any distributions under the program. The March 2026 prospectus supplement identifies NASDAQ as an execution option. (Source: PR Newswire prospectus supplement, March 2026.)

Company-level signals and operating constraints

No supplier-specific regulatory constraints were flagged in the relationship feed; as a result, the following are company-level signals derived from the public disclosures and financial profile:

  • Financing-first contracting posture: The ATM program signals that Aurora relies on opportunistic public-equity issuance to fund operations, which creates ongoing dilution as a structural financing lever.
  • Execution concentration: The ATM arrangement centralizes capital-raising activity through a named agent and exchange mechanisms, which creates single-point execution risk even if multiple venues are allowed.
  • Operational criticality to suppliers: Given negative net income and negative returns on equity, suppliers face higher counterparty risk, so contractual protections, advance payment terms, or shorter payment cycles are prudent.
  • Maturity and disclosure discipline: Aurora operates as a publicly reporting issuer with recent SEC disclosures around the ATM, which benefits counterparties through predictable information flows and timely updates.

Final read for investors and operators

Aurora’s supplier profile is defined by an operationally viable product engine moderated by ongoing capital needs that are being managed via an ATM equity program. For investors, the ATM program provides a clear lever for balance-sheet support while worsening dilution risk; for suppliers, it signals both an available pathway to liquidity for Aurora and a reason to tighten credit terms until operating profitability and cash flows stabilize.

If your organization needs deeper counterparty scoring or alerts tied to Aurora’s financing activity and execution partners, NullExposure provides continuous monitoring and supplier-risk scoring — start here: https://nullexposure.com/

For urgent supplier diligence requests or to subscribe to real-time counterparty alerts, visit https://nullexposure.com/ and connect directly with our team.